Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
|Videos|January 21, 2017
CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC
Author(s)Hans-Joachim Schmoll, MD, PhD
This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.
Advertisement
The CHARTA trial tested FOLFOX plus bevacizumab with or without irinotecan in patients with metastatic colorectal cancer.
In this video, Hans-Joachim Schmoll, MD, PhD, of the Martin Luther University Halle-Wittenberg in Halle, Germany, discusses results of the trial, covering the survival outcomes, subgroup analyses, and quality-of-life data.
The results of CHARTA (
Advertisement
Related to this article
A GDNS protocol did not significantly reduce loss of ASMI compared with usual care during chemoradiotherapy following esophagectomy in esophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
FDA Clears Triton Robotic Endoscopy System for Colon Procedures
3
ASTRO Issues First Clinical Practice Guideline on Radiation for Bladder Cancer
4
KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors
5